BioCentury | Jul 19, 2017
Clinical News

Fujifilm AD candidate fails in Phase II study

...delayed the advancement of cognitive decline vs. placebo. The high dose also significantly reduced biomarker phosphorylated tau (p-tau) 231...
BioCentury | Apr 29, 2015
Politics & Policy

FDA supports C-Path's AD, PD biomarkers

...measured in cerebrospinal fluid: beta amyloid 42, microtubule-associated protein tau (tau; MAPT; FTDP-17 ) and phosphorylated tau (p-tau) 231...
BioCentury | May 30, 2011
Emerging Company Profile

QR: Power of positivity

...45% (p<0.0006 and p<0.0001). It also significantly lowered microtubule-associated protein tau (MAPT; tau; FTDP-17 ), phosphorylated tau (p-tau) 231...
BioCentury | Sep 15, 2008
Company News

Applied NeuroSolutions diagnostic, neurology news

...partnerships. The company markets P-Tau 231 for research use. The antibody-based test measures levels of phosphorylated tau (p-tau) 231...
BioCentury | Dec 24, 2007
Clinical News

p-tau 231 ELISA test neurology data

...ELISA test Business: Neurology Molecular target: NA Description: Sandwich ELISA test measuring CSF levels of phosphorylated tau (p-tau) 231...
BioCentury | Jul 26, 2004
Company News

Applied NeuroSolutions other research news

An analysis of the cerebrospinal fluid (CSF) of AD patients showed p-tau was higher compared to healthy controls. Also, p-tau231 levels declined with disease progression. Data were presented at the International Conference on Alzheimer's Disease...
Items per page:
1 - 6 of 6